Johnson & Johnson vs. NewAmsterdam Pharma Company N.V. Ordinary Shares
JNJ
Johnson & Johnson
$271.22 +0.20%
VS NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares
$22.58 -0.70%
Johnson & Johnson (JNJ) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| JNJ | NAMS | |
|---|---|---|
| Market Cap | $653.61 billion | $2.70 billion |
| Revenue (TTM) | $97.93 billion | $7.12 million |
| Net Income (TTM) | $21.04 billion | $-259,504,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | NAMS | |
|---|---|---|
| P/E Ratio | 31.46 | — |
| Price / Book | 7.69 | 4.27 |
| Price / Sales | 6.67 | 379.04 |
JNJ and NAMS split the valuation factors evenly.
Profitability
| JNJ | NAMS | |
|---|---|---|
| Net Margin | 21.48% | -3644.21% |
| Return on Equity | 24.76% | -41.10% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | NAMS | |
|---|---|---|
| Dividend Yield | 1.98% | — |
| Payout Ratio | 62.18 | — |
JNJ and NAMS split the dividend factors evenly.
Risk & Sentiment
| JNJ | NAMS | |
|---|---|---|
| Short Interest | 0.67% | 0.01% |
NAMS leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, NAMS overview, NAMS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.